Ropinirole extended-release

Drug Profile

Ropinirole extended-release

Alternative Names: Requip CR; Requip LP; Requip Modutab/XL 24-hour; Requip XL; Requip XR; RequipP XL 24-hour Extended-Release Tablets; Ropinirole controlled-release; Ropinirole CR; Ropinirole ER; Ropinirole LP; Ropinirole PR; Ropinirole prolonged-release; Ropinirole XL; Ropinirole XR; SKF 101468A

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome

Most Recent Events

  • 17 Oct 2017 GlaxoSmithKline terminates a phase III trial in Parkinson's disease in Japan (PO) (NCT01929317)
  • 01 Jun 2015 GlaxoSmithKline completes a phase III trial in Parkinson's disease in Japan (PO) (NCT01929317)
  • 10 Jan 2014 Phase-III clinical trials in Parkinson's disease (monotherapy) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top